NevroNVRO
NVRO
About: Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Employees: 1,215
0
Funds holding %
of 7,290 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
18% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 39
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 130 [Q3] → 128 (-2) [Q4]
5.54% less ownership
Funds ownership: 101.56% [Q3] → 96.02% (-5.54%) [Q4]
37% less capital invested
Capital invested by funds: $212M [Q3] → $134M (-$77.8M) [Q4]
50% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $4.61M
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
30%
downside
Avg. target
$4.90
14%
downside
High target
$5.85
2%
upside
6 analyst ratings
0 positive
0%
5 neutral
83%
1 negative
17%
Canaccord Genuity William Plovanic 70% 1-year accuracy 33 / 47 met price target | 2%upside $5.85 | Hold Maintained | 7 Feb 2025 |
Piper Sandler Adam Maeder 75% 1-year accuracy 12 / 16 met price target | 2%upside $5.85 | Neutral Upgraded | 7 Feb 2025 |
Truist Securities Richard Newitter 74% 1-year accuracy 32 / 43 met price target | 18%downside $4.70 | Hold Maintained | 18 Dec 2024 |
Citigroup Joanne Wuensch 74% 1-year accuracy 35 / 47 met price target | 13%downside $5 | Neutral Maintained | 11 Dec 2024 |
Wells Fargo Nathan Treybeck 25% 1-year accuracy 1 / 4 met price target | 30%downside $4 | Equal-Weight Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 9 articles about NVRO published over the past 30 days
Neutral
PRNewsWire
23 hours ago
Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , Feb. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Positive
Zacks Investment Research
1 week ago
Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
2 weeks ago
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
Neutral
Business Wire
2 weeks ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the.
Positive
Zacks Investment Research
2 weeks ago
Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock?
Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
2 weeks ago
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
PRNewsWire
2 weeks ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nevro Corp. - NVRO
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Nevro Corp. (NYSE: NVRO ), relating to the proposed merger with Globus Medical.
Neutral
Business Wire
2 weeks ago
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders. Halper Sadeh encourages Nevro shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Nevro and its board of directors viola.
Neutral
Business Wire
2 weeks ago
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Nevro stockholders will receive only $5.85 per share, representing a total equity value of app.
Positive
Zacks Investment Research
1 month ago
Here's Why you Should Add Nevro Stock to Your Portfolio Now
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.
Charts implemented using Lightweight Charts™